1Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia [J]. N Engl J Med,2006,354:166-178.
2Kaspers GJL, Creutzig U. Pediatric acute myeloid leukemia:international progress and future directions[J]. Leukemia,2005,19:2025-2029.
3Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anticancer agents[J]. Oncogene ,2007,26(25):3714-3733.
4Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood,1994,83(2):435-445.
5Vose JM,Link BK,Grossbard ML,et al. Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389-397.
6Vose JM, Link BK, Grossbard ML, et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma [J]. Leuk Lymphoma,2005,46(11):1569-1573.
7Cheson BD. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma [J]. Biol Drugs,2005,19(5):309-322.
8Vose JM,Bierman PJ,Loberiza FR Jr,et al. Phase Ⅰ trial of (90) Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation[J]. Leuk Lymphoma,2007,48(4):683-690.
9Cooney-Qualter E, Krailo M, Angiolillo A, et al. A phase Ⅰ study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma:a Children's Oncology Group study[J]. Clin Cancer Res,2007,13(18 ,Part 2):5652s-5660s.
10Davies A J, Rohatiner AZ, Howell S, et al. Tositumomab and iodine Ⅰ 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma [J].J Clin Oncol,2004,22(8):1469-79.
